Overview | Research directions | Group members | Funding |Collaborations | Recent Publications
Overview
Main focus of the laboratory is to determine the crystallographic structures of proteins or 
protein complexes with a pathogenetic role in various human diseases. This knowledge is then exploited to develop chemical probes to better understand their functions and regulation mechanisms and in producing hit and lead compounds of potential pharmacological interest.
Research directions
- Bromodomains
Bromodomains are epigenetic reader modules recognizing acetylated lysines in histones and other proteins, regulating transcrip
tion and involved in various malignancies. The members of the BET subfamily of human bromodomains have been extensively studied in recent years with 12 BET inhibitors currently tested in clinical trials. Less is known about the function of other bromodomain-containing proteins such as BAZ2A and BAZ2B. As for BET bromodomains, the development of potent and selective inhibitors suitable for phenotypic profiling would help uncovering their biological roles. These could also prove therapeutically beneficial. - YTH domains
YTH domains are epitranscriptomic reader modules recognising methyladenosine-containing RNAs and regulating mRNA stability. Inhibitors of these domains would help in defining their involvement in various physiological and pathological pathways. - CK2
CK2 is a protein kinase involved in diverse cellular processes from apoptosis to differentiation. Its activity has been found el
evated in various cancers, especially haematological malignancies. Its anti-apoptotic role has been associated with its involvement in sustaining cancer growth and in protecting cancerous cells. A number of small molecules interfering with CK2 activity have been developed over the last years culminating in the so far unique CK2 inhibitor in clinical trials, CX-4945. The laboratory is actively involved in defining CK2 unusual self-inhibitory regulation mechanism and in developing new molecules of potential pharmacological interest as inhibitors of the human kinase (cancer) and of parasitic kinases (malaria, leishmaniasis and trypanosomiasis). - Lafora Disease
Lafora disease (LD) is a teenage-onset pathology characterized by spasmodic jerky contractions and epileptic seizures, which become increasingly frequent in the next years. Hallucination, dementia and vegetative state follow. Death occurs around age 25. The hallmark of LD is the presence in neurons of large neurotoxic inclusions, composed of aberrant and insoluble glycogen molecules. Structural dissection of the protein complexes involved in LD development and prognosis would help in identifying possible points of pharmacological intervention to subsequently target with small molecule inhibitors.
tion and involved in various malignancies. The members of the BET subfamily of human bromodomains have been extensively studied in recent years with 12 BET inhibitors currently tested in clinical trials. Less is known about the function of other bromodomain-containing proteins such as BAZ2A and BAZ2B. As for BET bromodomains, the development of potent and selective inhibitors suitable for phenotypic profiling would help uncovering their biological roles. These could also prove therapeutically beneficial.
evated in various cancers, especially haematological malignancies. Its anti-apoptotic role has been associated with its involvement in sustaining cancer growth and in protecting cancerous cells. A number of small molecules interfering with CK2 activity have been developed over the last years culminating in the so far unique CK2 inhibitor in clinical trials, CX-4945. The laboratory is actively involved in defining CK2 unusual self-inhibitory regulation mechanism and in developing new molecules of potential pharmacological interest as inhibitors of the human kinase (cancer) and of parasitic kinases (malaria, leishmaniasis and trypanosomiasis).Group members
- Graziano Lolli, PI
- Giulia Cazzanelli, postdoctoral fellow
- Andrea Dalle Vedove, postdoctoral fellow
Funding
My First AIRC Grant 2018-2022
Collaborations
- Prof. Amedeo Caflisch, Dept. of Biochemistry, University of Zurich, Switzerland
- Prof. Alessandro Quattrone, CIBIO, University of Trento, Italy
- Prof. Roberto Battistutta, Dept of Chemical Sciences, University of Padova, Italy
- Prof. Giuseppe Zagotto, Dept. of Pharmaceutical Sciences, University of Padova, Italy
- Dr. Paola Storici, Elettra Synchrotron, Trieste, Italy
Recent publications
Marchand J.R., Dalle Vedove A., Lolli G., Caflisch A. (2017) Discovery of Inhibitors of Four Bromodomains by Fragment-Anchored Ligand Docking. J. Chem. Inf. Model. 57, 2584-97.
Spiliotopoulos D., Wamhoff E.C., Lolli G.*, Rademacher C., Caflisch A. (2017) Discovery of BAZ2A bromodomain ligands. Eur. J. Med. Chem. 139, 564-72.
Lolli G.*, Naressi D., Sarno S., Battistutta R. (2017) Characterization of the oligomeric states of the CK2 α2β2 holoenzyme in solution. Biochem. J. 474, 2405-16.
Marchand J.R., Lolli G.* and Caflisch A. (2016) Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation. J. Med. Chem. 59, 9919-27.
Unzue A., Zhao H., Lolli G., Dong J., Zhu J., Zechner M., Dolbois A., Caflisch A. and Nevado C. (2016) The “gatekeeper” residue modulates the binding mode of acetyl indoles to bromodomains. J. Med. Chem. 59, 3087-97.
Lolli G.* and Caflisch A. (2016) High-throughput fragment docking into the BAZ2B bromodomain: Efficient in silico screening for X-ray crystallography. ACS Chem. Biol. 11, 800-7.
Lolli G.*, Pasqualetto E., Costanzi E., Bonetto G. and Battistutta R. (2016) The STAS domain of mammalian SLC26A5 prestin harbors an anion-binding site. Biochem. J. 473, 365-70.
Echalier A., Hole A.J., Lolli G., Endicott J.A. and Noble M.E.M. (2014) An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states. ACS Chem. Biol. 9, 1251-6.
Costa R., Arrigoni G., Cozza G., Lolli G., Battistutta R., et al. (2014) The lysine-specific demethylase 1 is a novel substrate of protein kinase CK2.Biochim. Biophys. Acta 1844, 722-9.
Cozza G., Girardi C., Ranchio A., Lolli G., Sarno S., et al. (2014) Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cell. Mol. Life Sci. 71(16), 3173-85.
Lolli G.*, Ranchio A. and Battistutta R. (2014) Active Form of the Protein Kinase CK2 α2β2 Holoenzyme Is a Strong Complex with Symmetric Architecture. ACS Chem. Biol. 9, 366-71.
* Corresponding or Co-corresponding author